Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
Synthetik Selected to Support Amentum-Led Team Hypersonics (UK) Industry Mission Partner February 23, 2026 Synthetik will deliver hypersonic modelling, environmental modelling and digital integration support, helping create knowledge hubs that accelerate a sovereign UK capability through collaboration with Government, academia, primes and SMEs.
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM February 23, 2026 Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy
Options Announces 15 Consecutive Years of SOC Compliance, Underlying Its Commitment to Delivering Secure Reliable Solutions February 23, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institutions, today announced that it has achieved SOC compliance for the 15th consecutive year, adhering to Type 2 SOC 1 & ISAE 3402, Type 2 SOC 2, and Type 2 SOC 3 standards. Danny Moore, President and CEO at Options said, “From the [...]
BAE Systems Announces 2025 Full Year Results February 23, 2026 Charles Woodburn, Chief Executive, said: “Our results highlight another year of strong operational and financial performance, thanks to the outstanding dedication of our employees. In a new era of defence spending, driven by escalating security challenges, we’re well positioned to provide both the advanced conventional systems and disruptive technologies needed to protect the nations we [...]
Soho Square Capital’s First Unicorn – Netomnia – to Be Acquired by InfraVia, Liberty Global and Telefónica Through Their Existing Joint Venture nexfibre February 23, 2026 Soho Square Capital LLP (“Soho Square”), an investment firm focused on financing established and growing UK and European SMEs, is pleased to confirm its portfolio company Netomnia, the UK’s second largest alternative fibre provider, has announced an agreement to be acquired by InfraVia, Liberty Global and Telefónica. The acquisition, which is subject to customary clearances, [...]
Motive Expands AI Platform to Automate Driver Qualification, Compliance and Workforce Records Management, Saving Teams from Time-Consuming Administrative Work February 23, 2026 New AI-powered Workforce Management capabilities eliminate manual document tracking, reduce compliance risk and help prevent costly downtime
Lady Mayor: London must deepen ties with America’s emerging powerhouses February 23, 2026 The US is more than just two coasts. Miami, Dallas and Texas are booking and London is perfectly placed to feel the benefits, says Susan Langley A huge part of the impact of the mayoralty is the 100 days spent overseas, championing the sector and deepening relationships in key markets. When people talk about UK-US [...]
Toshiba Showcases End-to-End Innovations Shaping What’s Next in Retail at EuroShop 2026 February 23, 2026 At EuroShop, Toshiba showcases intelligent, scalable solutions that combine AI, computer vision, and energy-efficient design to transform the future of retail.
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.